Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show.

Welcome to Helix Talk episode 119. I'm your co-host, Dr. Kane. And I'm Dr. Patel. And the topic we are going to discuss

is what's the buzz about benpidioic acid for dyspidemia, where we are going to discuss this

new latest and greatest treatment for dysepidemia and kind of dive into its pharmacology,

its approved uses, and what the current clinical evidence as it stands.

Dr. Patel, before we even started this episode when you mentioned this particular drug,

I had not heard of it at all. So I'm actually really excited to learn more about it.

And given how common dyslipidemia is in terms of patients that are on statins and isetamib and things like that,

I can potentially foresee this being a big drug that comes up a lot for anyone exposed to the

healthcare environment in the future given how common treating dyslipidemia is and how this is

kind of a new feather in the cap of the treatment plan for these patients.

And I agree with you, Dr. Kane. The buzz actually has been going on since 2019,

and the FDA approved this agent in late February, early March of 2020. But, you know, due to the

current pandemic, the buzz was not really there.

But it is, like you said, it's one of the new kid on the block for the dysopidemia treatment.

And I think it's worth the attention for an episode.

So let's get started with the patient case that kind of puts the entire discussion in context.

So we have a Casey who's a 57-year-old Caucasian female has a history of

...